Edition:
United States

Becton Dickinson and Co (BDX)

BDX on New York Consolidated

250.84USD
19 Jul 2019
Change (% chg)

$-2.99 (-1.18%)
Prev Close
$253.83
Open
$254.12
Day's High
$254.15
Day's Low
$250.71
Volume
758,995
Avg. Vol
1,311,461
52-wk High
$265.87
52-wk Low
$208.62

Summary

Name Age Since Current Position

Vincent Forlenza

65 2017 Chairman of the Board, Chief Executive Officer

Thomas Polen

45 2018 President, Chief Operating Officer

Christopher Reidy

61 2013 Chief Financial Officer, Executive Vice President, Chief Administrative Officer

Betty Larson

42 2018 Executive Vice President- Human Resources, Chief Human Resources

Samrat Khichi

51 2017 Executive Vice President, General Counsel

James Borzi

50 2017 Executive Vice President - Global Operations, Chief Supply Chain Officer

Simon Campion

47 2018 Executive Vice President and President, BD Interventional Segment

Roland Goette

56 2017 Executive Vice President, President - EMEA

Patrick Kaltenbach

55 2018 Executive Vice President, President - Life Sciences

James Lim

54 2012 Executive Vice President and President, Greater Asia

Alberto Mas

57 2018 Executive Vice President, President - Medical Segment

Charles Bodner

47 2018 Senior Vice President, Corporate Finance, and Chief Accounting Officer and Principal Accounting Officer

Catherine Burzik

68 2013 Independent Director

R. Andrew Eckert

57 2016 Independent Director

Claire Fraser

63 2006 Independent Director

Jeffrey Henderson

54 2018 Independent Director

Christopher Jones

63 2010 Independent Director

Marshall Larsen

70 2015 Lead Independent Director

David Melcher

64 2017 Independent Director

Claire Pomeroy

63 2014 Independent Director

Rebecca Rimel

68 2012 Independent Director

Timothy Ring

61 2017 Independent Director

Bertram Scott

67 2002 Independent Director

Monique Dolecki

IR Contact Officer

Biographies

Name Description

Vincent Forlenza

Mr. Vincent A. Forlenza is a Chairman of the Board, Chief Executive Officer of Becton, Dickinson and Company. He became BD’s Chairman in 2012 and was elected its Chief Executive Officer in 2011. He also served as BD’s President from 2009 to April 2017, and as its Chief Operating Officer from July 2010 to October 2011. He is a director of the Advanced Medical Technology Association (AdvaMed), an international medical technology trade organization, a director of the Quest Autism Foundation, and a member of the Board of Trustees of The Valley Health System. Mr. Forlenza also is a director of Moody’s Corporation. Mr. Forlenza has been with BD for over 37 years in a number of different capacities, including strategic planning, business development, research and development and general management, and in overseas roles. Mr. Forlenza brings to the Board extensive business and industry experience, and provides the Board with a unique perspective on BD’s strategy and operations, particularly in the area of new product development.

Thomas Polen

Mr. Thomas E. Polen is President, Chief Operating Officer of the Company. He was Executive Vice President and President - Medical Segment from October 2014 to April 2017; and Group President from October 2013 to October 2014.

Christopher Reidy

Mr. Christopher R. Reidy is Chief Financial Officer, Executive Vice President, Chief Administrative Officer of the company. He joins BD from ADP Corporation, where he served as Corporate Vice President and CFO for six years. Prior to ADP, Mr. Reidy’s more than 30 years of experience includes serving as CFO at NBA Properties, Inc.; Vice President, Controller & Chief Accounting Officer and division CFO roles at AT&T Corporation; and Audit Partner at Deloitte & Touche. Mr. Reidy, a Certified Public Accountant, earned his MBA from Harvard University and his B.S. in accounting from St. Francis College.

Betty Larson

Ms. Betty D. Larson Is an Executive Vice President- Human Resources, Chief Human Resources of the Company. She was Vice President of Human Resources, Interventional Segment from December 2017 to July 2018; Vice President, Human Resources, C.R. Bard, Inc. from September 2014 to December 2017; and prior thereto, Vice President, Human Resources - Global Medical Products Business, Baxter International.

Samrat Khichi

Mr. Samrat S. Khichi Is an Executive Vice President, General Counsel of the company. He was Senior Vice President, General Counsel and Corporate Secretary, C.R. Bard, Inc. from July 2014 to December 2017; and prior thereto, Chief Administrative Officer, Senior Vice President, General Counsel and Secretary, Catalent Pharma Solutions, a portfolio company of The Blackstone Group.

James Borzi

Mr. James W. Borzi Is Executive Vice President of Global Operations, Chief Supply Chain Office of the Company. Vice President, Global Operations from 2015 to October 2017; and Vice President, Global Manufacturing from 2013 to 2015.

Simon Campion

Mr. Simon Campion has been appointed Executive Vice President and President, BD Interventional Segment of the Company. Worldwide President, BD Interventional - Surgery from December 2017 to September 2018; President, Davol (now part of our Surgery business), C.R. Bard, Inc. from July 2015 to December 2017; and prior thereto, Vice President and General Manager, Davol.

Roland Goette

Mr. Roland Goette is Executive Vice President, President - EMEA of the Company. He was President, Europe from October 2014 to May 2017; and prior thereto, Vice President and General Manager - Medical Surgical Systems, Western Europe.

Patrick Kaltenbach

Mr. Patrick Kaltenbach is Executive Vice President, President - Life Sciences of the Company. He was Senior Vice President and President, Life Sciences and Applied Markets Group, Agilent Technologies, Inc. from November 2014 to April 2018; Vice President and General Manager of Agilent’s Life Sciences Products and Solutions organization from January 2014 to November 2014; and prior thereto, Vice President and General Manager of the Life Sciences Products and Solutions organization.

James Lim

Mr. James Lim is an Executive Vice President and President, Greater Asia of the Company. He served as Vice President and General Manager, Central Asia Pacific and Operations Since June 2012.

Alberto Mas

Mr. Alberto Mas is Executive Vice President, President - Medical Segment of the Company effective May 29 2018. He was Executive Vice President and President - Life Sciences Segment from October 2016 to June 2018; and Worldwide President - Diagnostic Systems from October 2013 to October 2016.

Charles Bodner

Mr. Charles R. Bodner is appointed as Senior Vice President, Corporate Finance, and Chief Accounting Officer and Principal Accounting Officer of the company effective July 1, 2018.

Catherine Burzik

Ms. Catherine M. Burzik is Independent Director of the Company. From 2006 until the sale of the company in 2012, she served as President and Chief Executive Officer of Kinetic Concepts, Inc., a medical device company specializing in the fields of wound care and regenerative medicine. Prior thereto, she was President of Applied Biosystems and President of Ortho-Clinical Diagnostics, Inc., a Johnson & Johnson company. Ms. Burzik also is a director of Haemonetics Corporation. Ms. Burzik is a seasoned executive in the healthcare industry, having led major medical device, diagnostic, diagnostic imaging and life sciences businesses. She contributes strong strategic, product development and leadership expertise, and extensive knowledge of the global healthcare field.

R. Andrew Eckert

Mr. R. Andrew Eckert is Independent Director of the Company. Since April 2017, he has served as President and Chief Executive Officer of Acelity L.P. Inc., a global wound care company. From 2015 until the sale of the company in 2016, he served as the Chief Executive Officer of Valence Health, Inc., a healthcare information technology and services company. Prior thereto, Mr. Eckert served as Chief Executive Officer of TriZetto Corporation, a healthcare IT solutions firm, and Chief Executive Officer of CRC Health Group, a provider of specialized behavioral healthcare services. Mr. Eckert also is a director of Acelity L.P. Inc. and the Chairman of Varian Medical Systems. Mr. Eckert is a leader in the growing field of healthcare information technology, with extensive experience as an executive officer of several healthcare companies. He has a deep knowledge of operations, strategic planning, product development and marketing, and has valuable corporate governance insight gained from having served as a director of several public companies.

Claire Fraser

Ms. Claire M. Fraser, Ph.D is Independent Director of the Company. Since 2007, she has been Director of the Institute for Genome Sciences and a Professor of Medicine at the University of Maryland School of Medicine in Baltimore, Maryland. From 1998 to 2007, she served as President and Director of The Institute for Genomic Research, a not-for-profit center dedicated to deciphering and analyzing genomes. Dr. Fraser also serves on the Board of the American Association for the Advancement of Science, the Maryland Technology Development Corporation (TEDCO) and Ohana Biosciences Inc. Dr. Fraser is a prominent scientist with a strong background in infectious diseases and molecular diagnostics, including the development of novel diagnostics and vaccines. She also brings considerable managerial experience in her field.

Jeffrey Henderson

Mr. Jeffrey W. Henderson Is an Independent Director of the Company. He has been an Advisory Director to Berkshire Partners LLC, a private equity firm, since September 2015. He served as Chief Financial Officer of Cardinal Health Inc., a global healthcare services company, from May 2005 to November 2014. Prior to joining Cardinal Health, Mr. Henderson held multiple positions at Eli Lilly and General Motors, including international positions. Mr. Henderson also is Non-Executive Chair of Qualcomm, Inc. and a director of FibroGen, Inc. and Halozyme Therapeutics, Inc. Mr. Henderson is an experienced healthcare executive who brings to the Board a deep knowledge of the industry, along with strong financial, strategic and operational expertise and significant international experience. Mr. Henderson also brings valuable corporate governance experience from his service as a director of other public companies.

Christopher Jones

Mr. Christopher Ian Jones is Independent Director of the CompanyMr. Jones retired in 2001 as Chief Executive Officer of JWT Worldwide (previously known as J. Walter Thompson), an international marketing firm. He is a member of the Board of Trustees of The Pew Charitable Trusts, and a member of the Board of Directors of the Albert and Mary Lasker Foundation. He also is a director of the Cello Group, Chairman of Palmer Hargreaves, and a member of the Health Advisory Board of The Johns Hopkins University Bloomberg School of Public Health. Mr. Jones contributes an important international perspective based on his distinguished career as a marketing leader and head of a global marketing firm. He offers substantial marketing, strategic and managerial expertise derived from his broad range of activities in the field.

Marshall Larsen

Mr. Marshall O. Larsen is Lead Independent Director of the Company. Mr. Larsen retired in 2012 as Chairman, President and Chief Executive Officer of Goodrich Corporation, a supplier of systems and services to the aerospace and defense industry. Mr. Larsen also is a director of Air Lease Corporation, Lowe’s Companies, Inc. and United Technologies Corporation. As a veteran chief executive officer of a public company, Mr. Larsen offers the valuable perspective of an individual with highly-developed executive leadership and financial and strategic management skills in a global manufacturing company. These qualities reflect considerable domestic and international business and financial experience.

David Melcher

Lt. Gen. David F. Melcher is Independent Director of the company. He had served as a Bard director since 2014. In December 2017, he retired as President and Chief Executive Officer of Aerospace Industries Association, a trade association representing major aerospace and defense manufacturers and suppliers, a position he had held since 2015. From 2011 to 2015, Mr. Melcher was Chief Executive Officer, President and a member of the Board of Directors of Exelis Inc., a public diversified, global aerospace defense, information and technology services company. Prior to 2008, Lieutenant General (Ret.) Melcher spent 32 years of distinguished service in the U.S. Army. He also is a director of Cubic Corporation. Mr. Melcher brings strong executive experience as a result of his many years in leadership positions in the defense community and as a former chief executive officer of a public company. Mr. Melcher offers the perspective of a seasoned executive with extensive experience and expertise in the areas of domestic and international business, program management, strategy development, finance and IT.

Claire Pomeroy

Ms. Claire Pomeroy is Independent Director of the Company. Since 2013, she has served as the President of the Albert and Mary Lasker Foundation, a private foundation that seeks to improve health by accelerating support for medical research through recognition of research excellence, public education and advocacy. Prior thereto, Dr. Pomeroy served as Dean of the University of California, Davis (“UC Davis”) School of Medicine, and Chief Executive Officer of the UC Davis Health System. Dr. Pomeroy also is Chair of the Board of Directors of the Foundation for Biomedical Research and the Sierra Health Foundation, and Vice Chairman of the Board of Trustees of The New York Academy of Medicine. She is a member of the Board of Trustees of the New York Blood Center and the Morehouse School of Medicine. Dr. Pomeroy is an expert in infectious diseases, with broad experience in the area of healthcare delivery, health system administration, higher education, medical research and public health. She brings to the Board important perspectives in the areas of patient care services, global health and health policy.

Rebecca Rimel

Ms. Rebecca W. Rimel is Independent Director of the Company. Since 1994, she has served as President and Chief Executive Officer of The Pew Charitable Trusts, a public charity that works to improve public policy and inform the public. Ms. Rimel previously served as Assistant Professor in the Department of Neurosurgery at the University of Virginia Hospital and also as Head Nurse of its medical center emergency department. Ms. Rimel also is a director of BioTelemetry, Inc. and a director/trustee of various Deutsche mutual funds. Ms. Rimel brings executive leadership and extensive experience in public policy and advocacy, particularly in the area of healthcare. She also offers the perspective of someone with a strong background in the healthcare field.

Timothy Ring

Mr. Timothy M. Ring is Independent Director of the company. Mr. Ring has been a director since BD’s acquisition of Bard in 2017, at which time he was serving as Bard’s Chairman and Chief Executive Officer, a position he had held since 2003. He also is a director of Quest Diagnostics Incorporated, and a co-founder of TEAMFund, Inc., an impact fund focused on delivering medical technology to sub-Saharan Africa and India. With over 20 years of experience in various leadership positions at Bard, including as Chairman and Chief Executive Officer, Mr. Ring offers a unique perspective on the Bard business. As an experienced chief executive officer of a public company, Mr. Ring contributes expertise in many facets of business, including strategy, product development and international operations, and has extensive experience in the healthcare industry.

Bertram Scott

Mr. Bertram L. Scott is Independent Director of the Company. Mr. Scott is Senior Vice President of Population Health of Novant Health, an integrated network of physician practices, outpatient centers and hospitals. He previously served as President and Chief Executive Officer of Affinity Health Plan, and as President, U.S. Commercial of CIGNA Corporation. Prior thereto, Mr. Scott served as Executive Vice President of TIAA-CREF and as President and Chief Executive Officer of TIAA-CREF Life Insurance Company. Mr. Scott also is a director of AXA Financial, Inc., Lowe’s Companies, Inc. and Tufts Health Plan. Mr. Scott possesses strong strategic, operational and financial experience from the variety of executive roles in which he has served during his career. He brings experience in corporate governance and business expertise in the insurance and healthcare fields.

Monique Dolecki

Monique N. Dolecki is an IR Contact Officer of the company.